# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number

k190397

# B Applicant

Immunalysis Corporation

# C Proprietary and Established Names

Immunalysis Carisoprodol Metabolite / Meprobamate Urine HEIA

D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>QBK</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 862.3590 -Meprobamate TestSystem</td><td rowspan=1 colspan=1>TX - ClinicalToxicology</td></tr></table>

# II Submission/Device Overview:

A Purpose for Submission: New device   
B Measurand: Carisoprodol metabolite (Meprobamate)   
C Type of Test: Qualitative Immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

The Immunalysis Carisoprodol Metabolite / Meprobamate Urine HEIA is a homogenous enzyme immunoassay for the qualitative analysis of carisoprodol metabolite, Meprobamate, at a cutoff of $2 8 0 ~ \mathrm { { n g / m L } }$ in human urine. The assay is intended for use in laboratories with automated clinical chemistry analyzers. This in vitro diagnostic device is for prescription use only.

The Immunalysis Carisoprodol Metabolite / Meprobamate Urine HEIA provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/ Mass Spectrometry (GC-MS) or Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

D Special Instrument Requirements:

Assay performance was established using the Olympus AU400e analyzer.

# IV Device/System Characteristics:

# A Device Description:

The Immunalysis Carisoprodol Metabolite / Meprobamate Urine HEIA is based on the competition of carisoprodol labeled enzyme glucose-6-phosphate dehydrogenase (G6PDH) and the free Meprobamate in the urine sample for the fixed amount of sheep anti-carisoprodol antibody binding sites. In the absence of the free Meprobamate in the sample, the antibody binds the drug enzyme conjugate and enzyme activity is inhibited. This creates a dose response relationship between drug concentration in the urine and enzyme activity. The enzyme G6PDH activity is determined at $3 4 0 \mathrm { n m }$ spectrophotometrically by the conversion of nicotinamide adenine dinucleotide (NAD) to NADH.

# B Principle of Operation:

The Immunalysis Carisoprodol Metabolite / Meprobamate Urine HEIA is based on the competition of carisoprodol labeled enzyme glucose-6-phosphate dehydrogenase (G6PDH) and the free drug in the urine sample for the fixed amount of sheep anti-carisoprodol antibody binding sites. In the absence of the free drug in the sample, the antibody binds the drug enzyme conjugate and enzyme activity is inhibited. This creates a dose response relationship between drug concentration in the urine and enzyme activity. The enzyme G6PDH activity is determined at $3 4 0 \mathrm { n m }$ spectrophotometrically by the conversion of nicotinamide adenine dinucleotide (NAD) to NADH.

# V Substantial Equivalence Information:

A Predicate Device Name(s): LZI Carisoprodol Metabolite (Meprobamate) Enzyme Immunoassay   
B Predicate 510(k) Number(s): DEN170010

C Comparison with Predicate(s):

<table><tr><td rowspan=1 colspan=1>Device &amp; PredicateDevice(s):</td><td rowspan=1 colspan=1>k190397</td><td rowspan=1 colspan=1>DEN170010</td></tr><tr><td rowspan=1 colspan=1>Device Trade Name</td><td rowspan=1 colspan=1>ImmunalysisCarisoprodolMetabolite /Meprobamate UrineHEIA</td><td rowspan=1 colspan=1>LZI CarisoprodolMetabolite(Meprobamate) EnzymeImmunoassay</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Similarities</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended Use/IndicationsFor Use</td><td rowspan=1 colspan=1>For the analysis ofcarisoprodol metabolite(meprobamate) inhuman urine.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Test Principle</td><td rowspan=1 colspan=1>Homogeneous EnzymeImmunoassay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>User Environment</td><td rowspan=1 colspan=1>Laboratory Use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Matrix</td><td rowspan=1 colspan=1>Human Urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Mass spectrometryconfirmation</td><td rowspan=1 colspan=1>Required to confirmpreliminary positiveanalytical results</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Differences</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Calibrator material</td><td rowspan=1 colspan=1>Carisoprodol</td><td rowspan=1 colspan=1>Meprobamate</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Polyclonal sheepantibodies tocarisoprodol</td><td rowspan=1 colspan=1>Monoclonal mouseantibodies tomeprobamate</td></tr></table>

# VI Standards/Guidance Documents Referenced:

The sponsor satisfied all special controls as outlined in 21 CFR 862.3590.

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

The following laboratory performance studies were performed to determine substantial equivalence of the Immunalysis Carisoprodol Urine HEIA to the predicate device.

# Precision/ Cutoff Characterization

A precision/Cutoff Characterization study for meprobamate was performed for ten days using three product lots with two runs per day in replicates of four on drug free urine $( \mathrm { N } { = } 8 0 )$ ) spiked with meprobamate to concentrations of the equivalent of the meprobamate cutoff and $\pm 2 5 \%$ , $\pm 5 0 \%$ , $\pm 7 5 \%$ , and $\pm 1 0 0 \%$ of the cutoff. The spiked concentrations were confirmed by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). The study verified that the cutoff serves as a boundary between a negative and positive interpretation of a qualitative result.

Precision test results in qualitative mode are presented in the table below:

<table><tr><td rowspan=2 colspan=1>MeprobamateConcentration(ng/mL)</td><td rowspan=2 colspan=1>% ofCutoff</td><td rowspan=2 colspan=1>SampleSize</td><td rowspan=1 colspan=3>Result</td></tr><tr><td rowspan=1 colspan=1>Lot 1</td><td rowspan=1 colspan=1>Lot 2</td><td rowspan=1 colspan=1>Lot 3</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-100%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Negative</td><td rowspan=1 colspan=1>80 Negative</td><td rowspan=1 colspan=1>80 Negative</td></tr><tr><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Negative</td><td rowspan=1 colspan=1>80 Negative</td><td rowspan=1 colspan=1>80 Negative</td></tr><tr><td rowspan=1 colspan=1>140</td><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Negative</td><td rowspan=1 colspan=1>80 Negative</td><td rowspan=1 colspan=1>80 Negative</td></tr><tr><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Negative</td><td rowspan=1 colspan=1>80 Negative</td><td rowspan=1 colspan=1>80 Negative</td></tr><tr><td rowspan=1 colspan=1>280</td><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>40 Neg/40 Pos</td><td rowspan=1 colspan=1>38 Neg/42 Pos</td><td rowspan=1 colspan=1>39 Neg/41 Pos</td></tr><tr><td rowspan=1 colspan=1>350</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Positive</td><td rowspan=1 colspan=1>80 Positive</td><td rowspan=1 colspan=1>80 Positive</td></tr><tr><td rowspan=1 colspan=1>420</td><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Positive</td><td rowspan=1 colspan=1>80 Positive</td><td rowspan=1 colspan=1>80 Positive</td></tr><tr><td rowspan=1 colspan=1>490</td><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Positive</td><td rowspan=1 colspan=1>80 Positive</td><td rowspan=1 colspan=1>80 Positive</td></tr><tr><td rowspan=1 colspan=1>560</td><td rowspan=1 colspan=1>+100%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>80 Positive</td><td rowspan=1 colspan=1>80 Positive</td><td rowspan=1 colspan=1>80 Positive</td></tr></table>

# 2. Analytical Specificity/Interference:

# Specificity and Cross-Reactivity

Compounds that were determined by the sponsor to be structurally and functionally similar to meprobamate were spiked into drug-free urine at levels that will yield a result that is equivalent to the cutoff and were evaluated as potential cross-reactant in the test device. Each compound was evaluated in replicates of four. Each compound was an independent spike and no drug mixes were used.

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>CompoundConc. (ng/mL)</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>Cross-Reactivity (%)</td></tr><tr><td rowspan=1 colspan=1>Meprobamate</td><td rowspan=1 colspan=1>280</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Carisoprodol</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>280</td></tr><tr><td rowspan=1 colspan=1>Buprenorphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Codeine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Darunavir</td><td rowspan=1 colspan=1>200,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>N/D</td></tr><tr><td rowspan=1 colspan=1>Dihydrocodeine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Efavirenz</td><td rowspan=1 colspan=1>200,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>N/D</td></tr><tr><td rowspan=1 colspan=1>Felbamate</td><td rowspan=1 colspan=1>120,000</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>0.2</td></tr><tr><td rowspan=1 colspan=1>Hydrocodone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Hydromorphone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Meperidine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Methocarbamol</td><td rowspan=1 colspan=1>200,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>N/D</td></tr><tr><td rowspan=1 colspan=1>Mitomycin C</td><td rowspan=1 colspan=1>200,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>N/D</td></tr><tr><td rowspan=1 colspan=1>Morphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Morphine-3-glucuronide</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Morphine-6-glucuronide</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Naloxone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Naltrexone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Neostigmine</td><td rowspan=1 colspan=1>200,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>N/D</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Norcodeine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Normorphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Oxycodone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Oxymorphone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Propoxyphene</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Retigabine</td><td rowspan=1 colspan=1>200,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>N/D</td></tr><tr><td rowspan=1 colspan=1>Ritonavir</td><td rowspan=1 colspan=1>200,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>N/D</td></tr><tr><td rowspan=1 colspan=1>Rivastigmine</td><td rowspan=1 colspan=1>200,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>N/D</td></tr><tr><td rowspan=1 colspan=1>Tramadol</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Trazadone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Venlafaxine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;0.1%</td></tr><tr><td rowspan=1 colspan=1>Zafirlukast</td><td rowspan=1 colspan=1>200,000</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>N/D</td></tr></table>

# Interference – Structurally Unrelated Compounds

Structurally unrelated compounds were evaluated by spiking the potential interferent at concentrations of at least $5 0 ~ \mu \mathrm { g / m L }$ into drug free urine containing analyte at $\pm 2 5 \%$ of the cutoff. The levels of structurally unrelated compounds that did not interfere in the assay are presented in the table below.

<table><tr><td colspan="3" rowspan="1">Compounds for which interference with the assay was not detected</td></tr><tr><td colspan="1" rowspan="1">4-Bromo-2,5,Dimethoxyphenethylamine</td><td colspan="1" rowspan="1">Dehydronorketamine</td><td colspan="1" rowspan="1">Naproxen</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">Delta-9-THC</td><td colspan="1" rowspan="1">Nitrazepam</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic Acid</td><td colspan="1" rowspan="1">Doxepin</td><td colspan="1" rowspan="1">11-nor-9 carboxy THC</td></tr><tr><td colspan="1" rowspan="1">6-Acetylcodeine</td><td colspan="1" rowspan="1">Doxylamine</td><td colspan="1" rowspan="1">Nordiazepam</td></tr><tr><td colspan="1" rowspan="1">Alphenal</td><td colspan="1" rowspan="1">Ecgonine</td><td colspan="1" rowspan="1">Norketamine</td></tr><tr><td colspan="1" rowspan="1">6-Acetylmorphine</td><td colspan="1" rowspan="1">Ecgonine methyl ester</td><td colspan="1" rowspan="1">Norpropoxyphene</td></tr><tr><td colspan="1" rowspan="1">Alprazolam</td><td colspan="1" rowspan="1">EDDP</td><td colspan="1" rowspan="1">Norpseudoephedrine</td></tr><tr><td colspan="1" rowspan="1">7-Aminoclonazepam</td><td colspan="1" rowspan="1">EMDP</td><td colspan="1" rowspan="1">Nortriptyline</td></tr><tr><td colspan="1" rowspan="1">7-Aminoflunitrazepam</td><td colspan="1" rowspan="1">1R,2S(-)-Ephedrine</td><td colspan="1" rowspan="1">O-desmethyl tramadol</td></tr><tr><td colspan="1" rowspan="1">7-Aminonitrazepam</td><td colspan="1" rowspan="1">1S,2R(+)-Ephedrine</td><td colspan="1" rowspan="1">O-desmethyl venlafaxine</td></tr><tr><td colspan="1" rowspan="1">Amitriptyline</td><td colspan="1" rowspan="1">Ethyl glucuronide</td><td colspan="1" rowspan="1">Olanzapine</td></tr><tr><td colspan="1" rowspan="1">Amobarbital</td><td colspan="1" rowspan="1">Ethylmorphine</td><td colspan="1" rowspan="1">Oxazepam</td></tr><tr><td colspan="1" rowspan="1">S-(+)Amphetamine</td><td colspan="1" rowspan="1">Fenfluramine</td><td colspan="1" rowspan="1">PCP</td></tr><tr><td colspan="1" rowspan="1">Aprobarbital</td><td colspan="1" rowspan="1">Fentanyl</td><td colspan="1" rowspan="1">Pentobarbital</td></tr><tr><td colspan="1" rowspan="1">Barbital</td><td colspan="1" rowspan="1">Flunitrazepam</td><td colspan="1" rowspan="1">Pentazocine</td></tr><tr><td colspan="1" rowspan="1">Benzoylecgonine</td><td colspan="1" rowspan="1">Fluoxetine</td><td colspan="1" rowspan="1">Phenazepam</td></tr><tr><td colspan="1" rowspan="1">Benzylpiperazine</td><td colspan="1" rowspan="1">Flurazepam</td><td colspan="1" rowspan="1">Phenobarbital</td></tr><tr><td colspan="1" rowspan="1">Bromazepam</td><td colspan="1" rowspan="1">Haloperidol</td><td colspan="1" rowspan="1">Phentermine</td></tr><tr><td colspan="1" rowspan="1">Bupropion</td><td colspan="1" rowspan="1">Heroin</td><td colspan="1" rowspan="1">Phenylephedrine</td></tr><tr><td colspan="1" rowspan="1">Butabarbital</td><td colspan="1" rowspan="1">Hexobarbital</td><td colspan="1" rowspan="1">Phenytoin</td></tr><tr><td colspan="1" rowspan="1">Butalbital</td><td colspan="1" rowspan="1">11-hydroxy-delta-9-THC</td><td colspan="1" rowspan="1">Phenylpropanolamine</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">PMA</td></tr><tr><td colspan="1" rowspan="1">Cannabidiol</td><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">Prazepam</td></tr><tr><td colspan="1" rowspan="1">Cannabinol</td><td colspan="1" rowspan="1">Ketamine</td><td colspan="1" rowspan="1">Propranolol</td></tr><tr><td colspan="1" rowspan="1">Carbamazepine</td><td colspan="1" rowspan="1">Labetalol</td><td colspan="1" rowspan="1">Protriptyline</td></tr><tr><td colspan="1" rowspan="1">Chlordiazepoxide</td><td colspan="1" rowspan="1">Lamotrigine</td><td colspan="1" rowspan="1">R,R(-)-Pseudoephedrine</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">Levorphanol tartrate</td><td colspan="1" rowspan="1">S,S(+)-Pseudoephedrine</td></tr><tr><td colspan="1" rowspan="1">cis-Tramadol</td><td colspan="1" rowspan="1">Lidocaine</td><td colspan="1" rowspan="1">Ritalinic Acid</td></tr><tr><td colspan="1" rowspan="1">Clobazam</td><td colspan="1" rowspan="1">Lorazepam</td><td colspan="1" rowspan="1">Salicylic Acid</td></tr><tr><td colspan="1" rowspan="1">Clomipramine</td><td colspan="1" rowspan="1">Lorazepam Glucuronide</td><td colspan="1" rowspan="1">Secobarbital</td></tr><tr><td colspan="1" rowspan="1">Clonazepam</td><td colspan="1" rowspan="1">Lormetazepam</td><td colspan="1" rowspan="1">Sertraline</td></tr><tr><td colspan="1" rowspan="1">Clozapine</td><td colspan="1" rowspan="1">LSD</td><td colspan="1" rowspan="1">Sufentanil Citrate</td></tr><tr><td colspan="1" rowspan="1">Cocaine</td><td colspan="1" rowspan="1">Maprotiline</td><td colspan="1" rowspan="1">Talbutal</td></tr><tr><td colspan="1" rowspan="1">Cotinine</td><td colspan="1" rowspan="1">MDA</td><td colspan="1" rowspan="1">Tapentadol</td></tr><tr><td colspan="1" rowspan="1">Cyclobenzaprine</td><td colspan="1" rowspan="1">MDEA</td><td colspan="1" rowspan="1">Temazepam</td></tr><tr><td colspan="1" rowspan="1">Cyclopentobarbital</td><td colspan="1" rowspan="1">MDMA</td><td colspan="1" rowspan="1">Theophylline</td></tr><tr><td colspan="1" rowspan="1">Demoxepam</td><td colspan="1" rowspan="1">S(+)-Methamphetamine</td><td colspan="1" rowspan="1">Thiopental</td></tr><tr><td colspan="1" rowspan="1">Desakylflurazepam</td><td colspan="1" rowspan="1">Methadone</td><td colspan="1" rowspan="1">Thioridazine</td></tr><tr><td colspan="1" rowspan="1">Desipramine</td><td colspan="1" rowspan="1">Methaqualone</td><td colspan="1" rowspan="1">Triazolam</td></tr><tr><td colspan="1" rowspan="1">Dextromethorphan</td><td colspan="1" rowspan="1">Methoxetamine</td><td colspan="1" rowspan="1">Trifluoromethylphenyl-piperazine</td></tr><tr><td colspan="1" rowspan="1">Diazepam</td><td colspan="1" rowspan="1">Methylone</td><td colspan="1" rowspan="1">Trimipramine</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">Methylphenidate</td><td colspan="1" rowspan="1">Verapamil</td></tr><tr><td colspan="1" rowspan="1">Diphenhydramine</td><td colspan="1" rowspan="1">Midazolam</td><td colspan="1" rowspan="1">Zolpidem Tartrate</td></tr></table>

# Interference – Endogenous Compounds

Endogenous compounds and urine preservatives were evaluated by spiking the potential interferent into drug free urine containing meprobamate at $\pm 2 5 \%$ of the cutoff. Due to the interference of boric acid observed at $\pm 2 5 \%$ of the cutoff, potential interference was also evaluated at $\pm 5 0 \%$ of the cutoff. Other than boric acid, assay performance was not affected by all the other internally existing physiological conditions tested. Endogenous compounds tested that did not interfere in the assay are presented in the table below.

<table><tr><td rowspan=1 colspan=1>Acetone</td><td rowspan=1 colspan=1>1.0 g/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>1.5 g/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>0.002 g/dL</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>0.5 g/dL</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>1.0 g/dL</td></tr><tr><td rowspan=1 colspan=1>Galactose</td><td rowspan=1 colspan=1>0.01 g/dL</td></tr><tr><td rowspan=1 colspan=1>γ-Globulin</td><td rowspan=1 colspan=1>0.5 g/dL</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>2.0 g/dL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobulin</td><td rowspan=1 colspan=1>0.300 g/dL</td></tr><tr><td rowspan=1 colspan=1>Human SerumAlbumin</td><td rowspan=1 colspan=1>0.5 g/dL</td></tr><tr><td rowspan=1 colspan=1>Oxalic Acid</td><td rowspan=1 colspan=1>0.1 g/dL</td></tr><tr><td rowspan=1 colspan=1>Riboflavin</td><td rowspan=1 colspan=1>0.0075 g/dL</td></tr><tr><td rowspan=1 colspan=1>Sodium Azide</td><td rowspan=1 colspan=1>1% w/v</td></tr><tr><td rowspan=1 colspan=1>SodiumChloride</td><td rowspan=1 colspan=1>6.0 g/dL</td></tr><tr><td rowspan=1 colspan=1>Sodium Fluoride</td><td rowspan=1 colspan=1>1% w/v</td></tr><tr><td rowspan=1 colspan=1>Urea</td><td rowspan=1 colspan=1>6.0 g/dL</td></tr></table>

Boric acid interference test results are presented in the table below.

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>-50% Cutoff(50 ng/mL)Result</td><td rowspan=1 colspan=1>+50% Cutoff (150ng/mL) Result</td></tr><tr><td rowspan=1 colspan=1>Boric Acid(1%w/v)</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Negative</td></tr></table>

Boric Acid at $1 \% \ \mathrm { w / v }$ may cause false negative results. The assay should not be used to test samples which contain boric acid.

# 3. Assay Reportable Range:

Not applicable. This device is intended for qualitative use only.

The device is traceable to a commercially available, certified, standard material for which the concentration is verified by GC-MS or LC-MS/ MS.

Accelerated stability and real time studies have been conducted for the device. Protocols and acceptance criteria were described and found to be acceptable. The manufacturer claims that when stored un-opened at $2 { - } 8 \ ^ { \circ } \mathrm { C }$ , the device is stable for 12 months.

5. Detection Limit: See Precision/Reproducibility section in XII.A.1, above.

6. Assay Cut-Off:

Characterization of how the device performs analytically around the claimed cut-off concentration appears in the precision section, VII.A.1, above.

# B Comparison Studies:

# 1. Method Comparison with Predicate Device:

One hundred and sixty-seven (167) de-identified, unaltered leftover clinical urine samples obtained from clinical testing laboratories were analyzed for total carisoprodol at an assay cutoff of $2 8 0 ~ \mathrm { { n g / m L } }$ with the Immunalysis Carisoprodol Urine HEIA on the Olympus AU400e compared to results by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Method comparison results are presented in the tables below.

<table><tr><td rowspan=2 colspan=1>ImmunalysisMeprobamateUrine HEIAResult</td><td rowspan=1 colspan=4>LC-MS/MS Total Meprobamate Concentration</td><td rowspan=2 colspan=1>Agreement(%)</td></tr><tr><td rowspan=1 colspan=1>&lt; 140ng/mL(less than-50%cutoff)</td><td rowspan=1 colspan=1>140-279ng/mL(between -50% cutoffand cutoff)</td><td rowspan=1 colspan=1>280-420ng/mL(betweencutoff and+50% cutoff)</td><td rowspan=1 colspan=1>&gt; 420ng/mL(greaterthan +50%cutoff)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>104</td><td rowspan=1 colspan=1>100%(107/107)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>92% (55/60)</td></tr></table>

Results from this testing included three false positive samples with meprobamate concentrations less than $50 \%$ of the cutoff. It was determined in LC-MS/MS testing that each of these samples included carisoprodol, as described in the table below, which caused the positive device results.

<table><tr><td colspan="1" rowspan="1">Sample ID</td><td colspan="1" rowspan="1">QualitativeResult</td><td colspan="1" rowspan="1">Carisoprodol(ng/mL)</td></tr><tr><td colspan="1" rowspan="1">17990</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">147</td></tr><tr><td colspan="1" rowspan="1">17977</td><td colspan="1" rowspan="1">POS</td><td colspan="1" rowspan="1">148</td></tr><tr><td>18077</td><td>POS</td><td>750</td></tr></table>

2. Matrix Comparison:

Not applicable. Urine is the only claimed matrix for the candidate device.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable.

2. Clinical Specificity: Not applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):

To support their proposed cutoff of $2 8 0 ~ \mathrm { { n g / m L } }$ for detection of the carisoprodol metabolite meprobamate, the sponsor provided protocols for and results from a pharmacokinetic study. Urine samples in this study were evaluated both by the sponsor’s device as well as confirmatory LC-MS/MS testing. After review, it was determined that the sponsor’s proposed cutoff was clinically valid for the intended use of the device.

D Clinical Cut-Off: Not applicable.   
E Expected Values/Reference Range: Not applicable.

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.